IMMU fundamentals
Key facts
Market capitalization299.74 MSEK
Basic EPS (TTM)−2.67SEK
Founded2002
CEOErik Manting
Websitemendus.com
About
Mendus AB is a clinical-level biopharmaceutical company, which engages in the provision of allogeneic dendritic cell biology focused on the development of immunotherapies that address tumor recurrence and hard-to-treat established tumors. It operates under the Sweden and Netherlands geographic segments. The company was founded by Bengt Anders Andersson, Alex Karlsson-Parra, and AnnaCarin Wallgren in 2002 and is headquartered in Stockholm, Sweden.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
−44.00 M
−33.00 M
−22.00 M
−11.00 M
0.00
Revenue
Net income
Net margin %
Estimates
Revenue and Earnings forecasts and estimates accuracy
Dividends
Dividend yield, history and sustainability
IMMU does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future
Financial health
Financial position and solvency of the company